changebio.uk

What It Is

Change Bio positions itself as the manufacturing layer for “designed proteins,” aiming to close the gap between protein sequences and scalable production. Its website emphasizes that the current bottleneck is no longer protein design, but manufacturing and manufacturability validation. It is closer to a combination of life-science platform services and production technology licensing than a traditional general-purpose SaaS product.

Core Features

Its products are organized into three stages of the designed-protein lifecycle. In the Design stage, the nsure platform can turn sequences into expression strains in a customer’s own lab, reportedly in as little as one week, and supports library construction and screening in K. phaffii. In the Prototype stage, Rapid protein prototyping lets users submit sequences, after which Change Bio returns usable protein samples within a few weeks via K. phaffii fed-batch fermentation. In the Scale stage, it offers platform and production know-how licensing for industrial-scale operators. The website also mentions a planned pooled library screening launch in September 2026, intended to evaluate candidate-sequence manufacturability under conditions closer to production.

Pricing and Trial

The website does not disclose pricing, billing models, or the boundaries of service packages. nsure is currently in a Beta cohort phase, with 5 of 10 slots remaining. Participants exchange feedback for early access and receive direct technical support from the Change Bio team. Rapid protein prototyping is listed as “Available now,” while Scale Licensing is open for discussion.

Pros and Cons

Its main strength is a highly focused positioning: it builds a continuous path around K. phaffii expression, library construction, high-throughput screening, and industrial scale-up, making it suitable for protein engineering teams looking to accelerate design-build-test cycles. The drawbacks are also clear: commercial transparency is limited, with a lack of common enterprise procurement information such as pricing, SLAs, delivery standards, data security, compliance, permissions, APIs, and third-party integrations. nsure is still in Beta, so its real-world stability and scalability remain to be validated.

Best Fit and Access from China

It is suited to designed-protein companies, protein engineering labs, synthetic biology teams, and operators looking to license an industrial production platform. The website text does not make it possible to assess access from China, and payment methods are not disclosed. For biological samples, technical services, and cross-border collaboration, additional evaluation is needed around logistics, compliance, contracts, and alternative local CRO/CDMO resources.